Home > Rheumatology > EULAR 2022 > EULAR 2022 Highlights Podcast

EULAR 2022 Highlights Podcast

Presented by
Dr Rachel Giles, Medicom
EULAR 2022

In this episode (20:20), Medicom’s correspondent covers 6 presentations from the European Alliance of Associations for Rheumatology (EULAR 2022) annual meeting, held on-site in Copenhagen and virtual live from 1-4 June 2022, marking EULAR's 75th anniversary!
The topics discussed are:

  1. JAK inhibitor shows to be effective in non-radiographic axSpA
    Once-daily therapy with upadacitinib led to an Assessment of SpondyloArthritis International Society 40 (ASAS40) response in 45% of patients with active, non-radiographic axial spondylarthritis (nr-axSpA) at week 14 in the SELECT-AXIS-2 trial. This was the first phase 3 trial data of JAK inhibitors ever presented in this indication.
  2. Baricitinib shows great potential in juvenile idiopathic arthritis
    During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares. These occurred in more than half of the cases in the placebo group but only about 17% in the baricitinib group.
  3. TYK2 inhibition: A rising star in lupus therapy?
    Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial. Depending on the dosage, up to 58.2% of study drug recipients showed a Systemic Lupus Erythematosus Responder Index (SRI) 4 response, significantly more than on placebo.
  4. Antifibrotic therapy effective in patients with negative prognostic factors for lung function decline
    Previously, nintedanib has shown to slow lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial. A post-hoc analysis of this trial revealed that treatment benefit is also evident in patients with 4 characteristics associated with a fast decline in lung function.
  5. Treatment with bimekizumab beneficial in psoriatic arthritis
    The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a therapy for psoriatic arthritis (PsA). At week 16, over 40% of study participants reached an ACR50 response.
  6. IL-6 inhibition successful in treating polymyalgia rheumatica
    Sarilumab demonstrated positive results in the randomised, phase 3 SAPHYR trial for patients with polymyalgia rheumatica (PMR). Significantly more participants reached sustained remission and the risk of flares was reduced.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers

Posted on